FDA approves Susvimo for diabetic macular edema
The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema.
Feb 6, 2025
0
18
Amino Acids, Peptides, and Proteins: News and Research on Antibodies, Monoclonal
MeSH tree: D12.776.124.486.485.114.224
AI tool helps find life-saving medicine for rare disease
After combing through 4,000 existing medications, an artificial intelligence tool helped uncover one that saved the life of a patient with idiopathic multicentric Castleman's disease (iMCD). This rare disease has an especially ...
Feb 5, 2025
0
52
In HER2+ colorectal cancer, anti-HER2 therapy may be less toxic alternative
Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF genes (RAS/BRAF wild-type) are typically treated with EGFR inhibitors. For those whose tumors also ...
Jan 29, 2025
0
11
Phase III trial shows new treatment boosts cure rate for most common form of breast cancer
A Peter Mac-led international clinical trial has shown adding an immunotherapy drug to the chemotherapy that patients receive ahead of surgery can dramatically improve breast cancer cure rates.
Jan 28, 2025
0
45
Radiotherapy with cetuximab may be superior to radiotherapy alone for patients who undergo surgery for head, neck cancer
Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the head and neck (SCCHN) ...
Jan 27, 2025
0
15
Metronomic chemotherapy: A promising approach for pediatric neuroblastoma
Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease. Despite advances in treatment, survival rates for high-risk and ...
Jan 23, 2025
0
13
Phase III trial finds trastuzumab emtansine improves long-term survival in HER2 breast cancer
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and improved survival compared ...
Jan 15, 2025
0
48
Clinical trial: Off-the-shelf immunotherapy shows promise for B-cell lymphoma
A new type of cell-based immunotherapy shows promise for B-cell lymphomas, and due to innovations in manufacturing, could make future cellular immunotherapies less expensive and more accessible to patients.
Jan 14, 2025
0
33
Some maternal medications lower levels of protein, fat in breastmilk
Some maternal medications are associated with lower levels of protein and fat in breastmilk, according to a study published online Jan. 7 in JAMA Network Open.
Jan 10, 2025
0
13
'Explant' technique predicts a tumor's responsiveness to breast cancer treatment
Cancer researchers at the University of Leicester have developed a technique that could predict how well some breast cancer patients will respond to chemotherapy and antibody-directed cancer treatments.
Jan 10, 2025
0
52
